Early Access — free while we kick the tires
EdgarHawk

Klinger Shannon Thyme

Chief Legal Officer

Officer
1 filing analyzed · 1 company · Latest 2026-03-03

Companies

Company Buys Sells Direction
Moderna, Inc. MRNA 0 10 Net selling

Activity

March 2026
2026-03-03 Moderna, Inc. MRNA
high
Sell
13,885 shares
$726,047
Significance 6/10

CLO Klinger Shannon Thyme sold 13,885 shares ($726.0K) at $52.29; holdings reduced 18.9%; prior similar-ticker sell preceded 90d decline of -50.8%.

Klinger Shannon Thyme, Chief Legal Officer, sold 13,885 shares at $52.29 on 2026-03-02, reducing his post-transaction holdings to 59,689 shares (a reduction of 18.9% versus his pre-transaction holdings of 73,574 shares). His cross-ticker track record shows a 100.00% well-timed rate on 1 prior sell across all holdings, with an average 90-day return of -50.8%, indicating past sales executed ahead of subsequent declines. At MRNA specifically, his only prior recorded trade was a sell on 2024-06-10 that saw a 90-day return of -50.8%, establishing a pattern of well-timed exits at this ticker. The company is currently unprofitable with a full-year net loss of $-200,000,000 and has experienced steep annual revenue decline of -39.9%, creating fundamental headwinds. This sale occurs while MRNA trades at $49.83, approximately 7.0% below its 52-week high of $53.57, a modest discount but within recent volatility; the stock has gained 13.1% over 30 days and 97.9% over 90 days, suggesting the $52.29 transaction price was executed near recent strength.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access